Posted by Michael Wonder on 22 Jul 2023
Invivoscribe announces FDA approval of the LeukoStrat CDx FLT3 mutation assay to select patients with FLT3 ITD positive AML for treatment with Vanflyta
21 July 2023 - Invivoscribe is excited to announce that the LeukoStrat CDx FLT3 mutation assay has been approved by the US FDA to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukaemia who may be eligible to receive treatment with Daiichi Sankyo's Vanflyta (quizartinib).
The LeukoStrat CDx FLT3 mutation assay identifies FLT3-ITD positive acute myeloid leukaemia patients who may be treated with this newly approved targeted therapy.
